MDACC Study No:2008-0436 ( NCT No: NCT00702052)
Title:An open-label, single-arm phase II study of RAD001 in patients with mantle cell lymphoma who are refractory or intolerant to Velcade (bortezomib) therapy
Principal Investigator:Michael Wang
Treatment Agent:RAD001
Study Status:Terminated
Study Description:The goal of this clinical research study is to learn if Everolimus (RAD001) can
help to control MCL. The safety of this drug will also be studied.

You are being asked to allow extra blood to be drawn for biomarker testing.
Biomarkers are chemical "markers" in the blood/tissue that may be related to
your response to the study drug.
Hide details for General InformationGeneral Information

Disease Group:Lymphoma
Phase of Study:Phase II
Treatment Agents:RAD001
Treatment Location:Both at MDACC & outside MDACC at one or more Collaborating Sites or Institutions
Estimated Length of Stay in Houston:N/A
Supported By:Novartis
Return Visit:RAD001 will be taken daily fm Visit 2, Day 1until disease progression or
unacceptable toxicity or discontinuation from the study for any other reason.
On days when PK sample collection is performed, study drug administration will
occur at the clinic.
Home Care:Patients will be instructed to take RAD001 at the same time each day, 10 mg
orally once daily (qd), two 5 mg tablets at once (one tablet after another)
with a glass of water.

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Michael Wang
For Clinical Trial Enrollment:713-792-2860
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults